



**ISLB**  
INTERNATIONAL SOCIETY  
OF LIQUID BIOPSY



6<sup>TH</sup> ANNUAL CONGRESS  
**Liquid Biopsy**

November 23-25, 2024 | Denver, Colorado, USA

# PROGRAM BOOK



[2024.ISLB.INFO](https://2024.islb.info)



[#ISLB24](https://twitter.com/ISLB24)

**Explore resources  
to learn more about  
precision medicine  
in oncology**

**and how to improve  
patient access  
to molecular testing  
at your institution!**

*Lilly*

Available on  
**medical.lilly.com**

**Explore  
now**



# Table of Contents

- 4 Welcome Message
- 5 Host Organization
- 6 Committee
- 7 Venue Floorplan
- 8 Program at a Glance
- 11 Full Congress Program
- 21 ISLB Award Lectures
- 22 Official Networking Events
- 23 Congress Partners
- 24 Exhibit & Poster Hall Information
- 25 Exhibitor Listing
- 30 General Congress Information
- 32 Save the Date for 2025
- 33 Poster Listing



# Welcome Message

Welcome to the 6th Annual Congress of Liquid Biopsy: “Advancing and Accelerating Access of Liquid Biopsy” (ISLB 2024) in the captivating city of Denver, Colorado, USA.

Liquid biopsy stands at the forefront of medical innovation, poised to revolutionize cancer treatment and patient care. With exponential growth and transformative potential, our congress aims to propel the global adoption of liquid biopsies, dismantling barriers hindering their integration into routine clinical practice. Education, technological accessibility, standardization, and other critical factors are pivotal in shaping the future of this field.

Building upon the success of our previous in-person gathering in Madrid, Spain, which drew over 500 attendees, ISLB 2024 promises unparalleled excellence. Our chosen venue, the Convention Center, boasts state-of-the-art facilities and amenities, ensuring a seamless and enriching experience for all participants.

While Colorado’s natural splendor is renowned, Denver’s vibrant urban landscape offers a wealth of cultural and culinary delights. From museums and galleries to a thriving restaurant scene, Denver invites exploration and enjoyment. And with Thanksgiving just around the corner, nearby mountain retreats provide an enticing option for further adventure.

We are confident that our attendees will relish the dynamic atmosphere of Denver, departing with cherished memories and newfound knowledge from this unforgettable scientific exchange.

Mark your calendars and join us in Denver on November 23-25, 2024, as we collectively shape the future of liquid biopsy. Together, let us make ISLB 2024 an unparalleled scientific gathering, empowering liquid biopsy professionals for the challenges ahead.

We look forward to welcoming you all!

**Christian Rolfo**

ISLB President

On behalf of the ISLB Executive Committee



# Host Organization

## About ISLB

The International Society of Liquid Biopsies (ISLB), founded in 2017 in Granada, Spain, aims to bring together healthcare professionals, primarily oncologists and those who have adopted liquid biopsies as a cutting-edge clinical tool. We are pleased to welcome liquid biopsy professionals from around the world, and we strive to serve as a link among key stakeholders in this field.

By joining ISLB, members become part of an international community of healthcare professionals involved in the management of cancer patients, sharing best practices and the latest advancements in liquid biopsy use to ensure the successful implementation of this approach in cancer treatment and other diseases that may benefit from it. Membership benefits include free or discounted access to Critical Reviews in Oncology/Hematology publications, savings of up to \$100 on registration fees for the ISLB Annual Congress, free access to on-demand videos in the ISLB Virtual Library, eligibility to volunteer and join ISLB Committees, access to ISLB's annual awards and grants, and opportunities for networking with patient associations and international liquid biopsy consortiums.



# Committee

## Executive Committee



**Christian Rolfo**

ISLB President  
*United States*



**Maria Jose Serrano**

ISLB Vice President  
*Spain*



**Umberto Malapelle**

ISLB Scientific Secretary  
*Italy*



**Eloisa Jantus Lewintre**

ISLB Treasurer  
*Spain*



**David Gandara**

ISLB CMO  
*United States*



**Massimo Cristofanilli**

ISLB Past President  
*United States*



# Venue Floorplan

- Plenary Sessions
- Exhibits, Posters, Showcase Theatre
- Breakout Sessions, Advisory Board Meetings (Friday Only)
- Registration Desk and Membership Zone
- Advisory Board Meetings (Friday Only)

# Program at a Glance

Saturday, November 23, 2024



# Program at a Glance

Sunday, November 24, 2024

08:00	<b>Industry Symposium: Guardant Health</b> 08:00 - 09:00   Adams B		 Continental Breakfast Provided
08:30			
09:00	<b>S05. Liquid Biopsy for Early Cancer Detection</b> 09:00 - 10:30   Adams B	<b>S06. Next Generation Technologies in Liquid Biopsy</b> 09:00 - 10:30   Spruce 3-4	
09:30			
10:00			
10:30	<b>Morning Break   Exhibit Hall   Poster Session</b> 10:30 - 12:00   Exhibit Hall (Adams C-D)		
11:00	<b>Showcase Theatre: OncoHost</b> 10:40 - 11:00   Exhibit Hall (Adams C-D)		 Refreshments Provided
11:30	<b>Showcase Theatre: Qiagen</b> 11:10 - 11:30   Exhibit Hall (Adams C-D)		
12:00			
12:30	<b>Industry Symposium: Foundation Medicine</b> 12:15 - 13:15   Adams B		 Lunch Box Provided
13:00	12:00 Lunch Box Pick Up		
13:30	<b>Afternoon Break 13:15 - 13:30</b>		
14:00	<b>S07. Future Perspectives in Liquid Biopsy</b> 13:30 - 15:00   Adams B	<b>Workshop: ctDNA : Preanalytical and Post Analytical Standardization Workshop</b> 13:30 - 15:00   Spruce 3-4	
14:30			
15:00			
15:30	<b>S08. Keynote Session</b> 15:10 - 16:30   Adams B		
16:00			
16:30			
17:00	<b>Industry Symposium: Thermo Fisher Scientific</b> 16:30 - 17:30   Adams B		
17:30			
18:00	<b>Young Career Round Tables</b> 17:30 - 19:00   Spruce 3-4		
18:30			
19:00			
19:30			
20:00			

# Program at a Glance

Monday, November 25, 2024

08:00	<b>Industry Symposium: OneCell Diagnostics</b> 8:00 - 9:00   Adams B	 Continental Breakfast Provided
08:30		
09:00	<b>OA01. Preferred Abstracts</b> 9:00 - 10:30   Adams B	
09:30		
10:00	<b>Morning Break   Exhibit Hall   Poster Session</b> 10:30 - 11:30   Exhibit Hall (Adams C-D)	 Refreshments Provided
10:30		
11:00	<b>S09. Accreditations and Minimal Requirements for Liquid Biopsy</b> 11:30 - 13:00   Adams B	
11:30		
12:00	<b>Best Abstract Award &amp; Closing Ceremony</b> 13:00 - 14:00   Adams B	
12:30		
13:00		
13:30		
14:00		



# Unlock the power of CTCs!



## Meet us at Booth 111

The Parsortix® PC1 system is the first FDA cleared medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis.

At its core is a unique method for capturing and harvesting intact CTCs and CTC clusters from whole blood for downstream analysis, which is non-invasive and can be repeated as often as needed.

At ANGLE we offer products for use in both clinical and research laboratories, as well as a bespoke biopharma testing service to support your clinical trial needs.

Meet our expert team to discover how CTCs can help enhance your work.

“Circulating tumour cells harvested by [the Parsortix PC1 system] are a good surrogate for tissue biopsies of the metastatic site”

**Julie E. Lang**  
Chief of Breast Surgery, Cleveland Clinic

[angleplc.com](http://angleplc.com)

# Full Congress Program

## SATURDAY, NOVEMBER 23, 2024

### 08:00 – 09:30 S01. Current Status of Circulating Tumor DNA in Selected Solid Tumors

Adams B

#### 08:00 – 08:05 Chair

David Gandara, ISLB - United States

#### 08:05 – 08:20 S01.01 Role of the Pathologist in Liquid Biopsy for Therapeutic Decision Making

Diana Ionescu, Bc Cancer, Ubc - Canada

#### 08:20 – 08:35 S01.02 Update on Liquid Biopsy in Breast Cancer

Massimo Cristofanilli, ISLB - United States

#### 08:35 – 08:50 S01.03 Liquid Biopsy in Lung Cancer: Recent Applications of ctDNA in Early-Stage NSCLC

David Gandara, ISLB - United States

#### 08:50 – 09:05 S01.04 Current Status of Liquid Biopsy in Prostate Cancer

Nicholas Mitsiades, University of California Davis Comprehensive Cancer Center - United States

### 09:30 – 11:00 S02. Navigating the Complex Landscape of Liquid Biopsy: Current Trends and Future Directions

Adams B

#### 09:30 – 09:35 Chairs

Eloisa Jantus Lewintre, ISLB - Spain

Christian Rolfo, ISLB - United States

#### 09:35 – 09:50 S02.01 Liquid Biopsy in Radiation Oncology: Current Status

Aadel Chaudhuri, Mayo Clinic - United States

#### 09:50 – 10:05 S02.02 Single Cell Analysis and Clonal Hematopoiesis. Implications in Liquid Biopsy for Solid Tumors.

Franco Izzo, Icahn School Of Medicine At Mount Sinai - United States

#### 10:05 – 10:30 S02.03 Rationale for Concurrent Tissue + Plasma ctDNA analysis at Cancer Diagnosis

Natasha Leighl, Princess Margaret Cancer Centre - Canada

#### 10:20 – 10:35 S02.04 Tumor Fraction Calculation in cfDNA

Christian Rolfo, ISLB - United States

#### 10:35 – 11:00 Panel Discussion

Umberto Malapelle, ISLB - Italy

Valsamo Anagonostou, Johns Hopkins School of Medicine - United States

**09:30 – 11:00 S03. Extracellular Vesicles and CTCs**

Spruce 3-4

**09:30 – 09:35 Chairs**

Maria Jose Serrano, ISLB - Spain

Nicola Fusco, European Institute of Oncology - Italy

**09:35 – 09:50 S03.01 Applicability of CTC Screening in Daily Clinical Practice**

Paul Hofman, IHU RespirERA - France

**09:50 – 10:05 S03.02 CTC in Breast Cancer**

Carolina Reduzzi, Weill Cornell Medicine - United States

**10:05 – 10:20 S03.03 Lipidomic Profiling of Extracellular Vesicles**

Julia Burnier, McGill University - Canada

**10:20 – 10:35 S03.04 Extracellular Vesicles as Potential Biomarkers for Diagnosis and Recurrence Detection of Hepatocellular Carcinoma**

Augusto Villanueva, Icahn School of Medicine at Mount Sinai - United States

**10:35 – 11:00 Panel Discussion**

Massimo Cristofanilli, ISLB - United States

Anthony Lucci, MD Anderson Cancer Center - United States

**11:00 – 12:30 Morning Break**

Exhibits/ Posters | Exhibit Hall (Adams C-D)

**REFRESHMENTS PROVIDED****12:30 – 12:45 Bio Break**

Outside Adams B

Pick up your Lunch Box Sponsored by Precision Cancer Consortium

**12:45 – 13:45 Industry Symposium: Precision Cancer Consortium | Adams B****LUNCH BOX PROVIDED****Expanding Access and Adoption of Liquid Biopsy in Routine Clinical Care: *Expert Insights, Practical Solutions, and Your Chance to Join the Conversation***

The Precision Cancer Consortium (PCC), believes that liquid biopsy plays a crucial role in expanding global access to comprehensive genomic profiling and improving patient outcomes. Join the PCC at their sponsored symposium, where Dr Simon Heeke will explore the contrast between utilization of comprehensive genomic profiling in academic settings with its use in community practice, and how liquid biopsy (LBx) can play a role in bridging this gap to improve patient access. Drs Paul Hofman and Bruna Pellini will then participate in a 'fireside chat', discussing the landscape, challenges, and real-world solutions surrounding LBx access and adoption.

*The Precision Cancer Consortium (PCC) is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at time of writing*

*PCC-108 | Date of prep: October 2024*

**14:00 – 15:30 Stakeholder Workshop**

Adams B

**14:00 – 14:05 Chair**

David Gandara, ISLB - United States

**14:05 – 14:45 Panel 1: Clinical Application of Liquid Biopsy: Greatest Challenges and Opportunities**

Hashem Alshurafa, Guardant Health - United States

Mary Redman, Fred Hutchinson Cancer Research Center - United States

Paz Vellanki, FDA - United States

Ola Khorshid, Nci Cairo University – Egypt

Daniel Hicks, IASLC - United States

David Kozono, Dana-Farber Brigham Cancer Center - United States

Jean-Francois Pouliot, Regeneron - United States

Ofer Sharon, OncoHost - Israel

Biljana Naumovic, Johnson &amp; Johnson - United States

**14:45 – 14:50 Chair**

Christian Rolfo, ISLB - United States

**14:50 – 15:30 Panel 2: Technology- Translational**

Abhijit Patel, Yale University - United States

Paz Vellanki, FDA - United States

Murry Wynes, Go2 for Lung Cancer - United States

David Kozono, Dana-Farber Brigham Cancer Center - United States

Luca Quagliata, Thermo Fisher Scientific - Italy

Adam Sowalsky, National Cancer Institute - United States

**15:30 – 15:45 Bio Break****15:45 – 17:15 S04. Award Lectures**

Adams B

**15:45 – 15:50 Chairs**

Maria Jose Serrano, ISLB - Spain

Christian Rolfo, ISLB - United States

**15:50 – 16:15 S04.01 Application of Circulating Tumor DNA Analyses to Unmet Clinical Needs**

Luis Diaz, Memorial Sloan Kettering - United States

**16:15 – 16:40 S04.02 ctDNA – From Proof-of-Principle to Clinical Implementation**

Ellen Heitzer, Medical University of Graz - Austria

**16:40 – 5:05 S04.03 Frontiers in Cell-free DNA Fragmentomics**

Dennis Lo, The Chinese University Of Hong Kong - Hong Kong

**17:15 – 18:15 Opening Ceremony**

Adams B

**17:15 – 17:20 ISLB activities during 2023**

Christian Rolfo, ISLB - United States

Maria Jose Serrano, ISLB - Spain

**17:20 – 17:25 Course of Advanced Study**

David Gandara, ISLB - United States

**17:25 – 17:30 Update on the Journal of Liquid Biopsy and CROH**

Umberto Malapelle, ISLB - Italy

**17:30 – 17:35 Relationship with the Other Societies**

Eloisa Jantus Lewintre, ISLB – Spain

**17:35 – 17:40 Presentation of the Communication Committee**

Yüksel Ürün, Ankara University School of Medicine; Department of Medical Oncology - Turkey

**17:40 – 17:45 Presentation of the Educational Committee**

Natasha Leighl, Princess Margaret Cancer Centre - Canada

**17:45 – 17:50 Presentation of the Young Committee**

Carolina Reduzzi, Weill Cornell Medicine - United States

**17:50 – 17:55 Presentation of the Quality and Accreditation Committee**

Nicola Fusco, European Institute of Oncology - Italy

**17:55 – 18:00 Presentation of the Publications Committee**

Charu Aggarwal, University of Pennsylvania - United States

**18:00 – 18:05 Presentation of the Membership Committee**

Bruna Pellini, Moffitt Cancer Center - United States

**18:05 – 18:10 Presentation of the Committee on Developing Countries**

Ola Khorshid, Nci Cairo University - Egypt

**18:10 – 18:15 Final Remarks**

Massimo Cristofanilli, ISLB - United States

**18:15 – 20:30 Welcome Reception - Supported by Thermo Fisher Scientific Exhibits/Posters**

Exhibit Hall (Adams C-D)

# SUNDAY, NOVEMBER 24, 2024

08:00 – 09:00 **Industry Symposium: Guardant Health**

Adams B



## **Infinite Possibilities: Expanding Utility and Enabling Analysis of Liquid Biopsy in Precision Oncology**

This symposium will highlight the innovation in liquid biopsy through epigenomics across the continuum of cancer care. We will highlight the nuances of epigenomics in carcinogenesis and its ability to extend utility of liquid biopsy beyond genomics-based technologies, particularly that of the Guardant Infinity platform. Additionally, we will highlight data – both generated at Guardant and outside of Guardant – that reviews the development of signatures and applications of epigenomics to further refine precision medicine. We will then highlight the current and future capabilities of multi-modal datasets to harness to continue biomarker discovery and outcomes-based research, highlighting the clinico-genomics database, Guardant INFORM.

09:00 – 10:30 **S05. Liquid Biopsy for Early Cancer Detection**

Adams B

09:00 – 09:05 **Chairs**

Christian Rolfo, ISLB - United States

Valsamo Anagnostou, Johns Hopkins School of Medicine - United States

09:05 – 09:20 **S05.01 Early Detection of Renal Cell Carcinoma**

Jacob Berchuck, Winship Cancer Institute of Emory University - United States

09:20 – 09:35 **S05.02 Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.**

Trevor Pugh, Princess Margaret Cancer Centre, Ontario Institute for Cancer Research - Canada

09:35 – 09:50 **S05.03 Early Detection in Lung Cancer**

Christian Rolfo, ISLB - United States

09:50 – 10:05 **S05.04 miRNAs in Blood and Urine as Companion Diagnostic Biomarkers in Genitourinary Tumours**

Marta Dueñas, Fundación de Investigación Biomédica Hospital 12 de Octubre - Spain

09:00 – 10:30 **S06. Next Generation Technologies in Liquid Biopsy**

Spruce 3-4

09:00 – 09:05 **Chairs**

Eloisa Jantus Lewintre, ISLB - Spain

Maria Jose Serrano, ISLB - Spain

09:05 – 09:20 **S06.01 Next Generation Trial Design in Liquid Biopsy**

Mary Redman, Fred Hutchinson Cancer Research Center - United States

**09:20 – 09:35 S06.02 The future of Bioinformatics in Liquid Biopsy Research**  
Giovanni Nigita, The Ohio State University Comprehensive Cancer Center - United States

**09:35 – 09:50 S06.03 ctDNA Methylation Analysis for Early Detection**  
Abhijit Patel, Yale University - United States

**09:50 – 10:05 S06.04 Multidimensional ctDNA Testing**  
Umberto Malapelle, ISLB - Italy

**10:05 – 10:30 Panel Discussion**  
Paul Hofman, IHU RespirERA - France  
Simon Patton, EMQN CIC - United Kingdom

**10:30 – 12:00 Morning Break  
Showcase Theatre/ Exhibits/ Posters**  
Exhibit Hall (Adams C-D)  
Showcase Schedule OncoHost: 10:40 – 11:00  
Qiagen: 11:10 – 11:30



**10:40 – 11:00 Showcase Theatre: OncoHost**  
Exhibit Hall (Adams C-D)

### **Cutting-Edge Biomarkers: How Proteomics and AI are Shaping the Future of Immunotherapy**

Given the intricate relationship between therapy, tumor, and host, biomarker development for immunotherapy requires a holistic, system-wide approach. Multicomponent biomarkers in the blood offer significant potential by providing a more complete view of the underlying biological signals.

Dr. Harel will discuss the challenges in developing biomarkers for immunotherapy and how these are being addressed through the PROphet platform. By harnessing plasma proteomics and machine learning algorithms, this platform enables the prediction of treatment efficacy and toxicity, offering a valuable tool for informing treatment decisions in non-small cell lung cancer and other indications.

Attendees will gain insights into how this innovative tool provides comprehensive clinical assessments, empowering physicians to make more informed, personalized treatment decisions with a single blood test.

**11:10 – 11:30 Showcase Theatre: Qiagen**  
Exhibit Hall (Adams C-D)

### **Evaluation of Preanalytical Workflows for Molecular Profiling of Urinary Cell-Free DNA in Malignant Diseases**

Ellen Heitzer, Medical University Graz - Austria

**12:00 – 12:15 Bio Break**  
Outside Adams B  
Pick up your Lunch Box Sponsored by Foundation Medicine

**ctDNA Revolution: Shaping the Future of Cancer Care with Next Generation Biomarkers and Real-Time Treatment Monitoring**

Foundation Medicine's symposium will explore the transformative role of circulating tumor DNA (ctDNA) in modern cancer care. As precision medicine advances, non-invasive ctDNA technologies are revolutionizing treatment selection and treatment response monitoring, offering real-time insights into treatment efficacy and even tumor evolution. This presentation will highlight cutting-edge developments, such as the use of ctDNA in monitoring applications, and how ctDNA can be used in adaptive trial design. You'll also learn how next-generation algorithms such as ctDNA tumor fraction and CH along with advanced genomic sequencing are enabling clinicians to gather deeper insights to tumor biology.

**13:15 – 13:30 Bio Break****13:30 – 15:00 S07. Future Perspectives in Liquid Biopsy**

Adams B

**13:30 – 13:35 Chairs**

Christian Rolfo, ISLB - United States

Natasha Leighl, Princess Margaret Cancer Centre - Canada

**13:35 – 13:50 S07.01 Immune-related Predictive Biomarkers in NSCLC**

Valsamo Anagonostou, Johns Hopkins School of Medicine - United States

**13:50 – 14:05 S07.02 HPV Circulating Tumor DNA**

Lillian Siu, Princess Margaret Cancer Centre - Canada

**14:05 – 14:20 S07.03 ctDNA for Monitoring Immunotherapy**

Erin Schenk, University of Colorado - United States

**14:20 – 14:35 S07.04 Liquid Biopsy in GI Cancer**

Sameek Roychowdhury, The Ohio State University - United States

**14:35 – 15:00 Panel Discussion**

Maria Jose Serrano, ISLB - Spain

David Gandara, ISLB - United States

**13:30 – 15:00 Workshop: ctDNA : Preanalytical and Post Analytical Standardization Workshop**

Spruce 3-4

**13:30 – 13:35 Chairs**

Nicola Fusco, European Institute of Oncology - Italy

Eloisa Jantus Lewintre, ISLB - Spain

**13:35 – 13:55 Lessons Learned from Quality Control Assessment Program on Liquid Biopsy**

Simon Patton, EMQN CIC - United Kingdom

**13:55 – 14:55 Workshop Panel**

Silvia Calabuig Fariñas, University of Valencia - Spain

Paul Hofman, IHU RespirERA - France

Ellen Heitzer, Medical University of Graz - Austria

Jose Luis Costa, Thermo Fisher Scientific - Portugal

Simon Heeke, UT MD Anderson Cancer Center - United States

**14:45 – 15:00 Panel Discussion****15:00 – 15:10 Bio Break****15:10 – 16:30 S08. Keynote Session**

Adams B

**15:10 – 15:15 Chair**

Christian Rolfo, ISLB - United States

**15:15 – 15:35 S08.01 Cell-free DNA Screening for Nasopharyngeal Carcinoma**

Dennis Lo, The Chinese University Of Hong Kong - Hong Kong

**15:35 – 15:55 S08.02 Blood Based Test for Colorectal Cancer Screening**

Daniel Chung, Massachusetts General Hospital - United States

**15:55 – 16:15 S08.03 Early Detection of Molecular Residual Disease limitations and Opportunities**

Aadel Chaudhuri, Mayo Clinic - United States

**16:30 – 17:30 Industry Symposium: Thermo Fisher Scientific**

Adams B

**Liquid Biopsy, Quo Vadis? Real-World Clinical Case Examples in 2024 and Future Applications in Oncology**

This symposium is set to offer an engaging and informative session for clinicians, researchers, and industry professionals. By featuring real-world cases and fostering dynamic discussions, it will serve as a platform for exchanging valuable knowledge and driving forward the conversation on the future of liquid biopsy in oncology.

Each panelist will present their unique cases, showcasing how liquid biopsy has been effectively used in their respective clinical practices. The format is designed to promote interaction not only between the panelists but also with the audience. The emphasis will be on creating a lively dialogue, where panelists will share their insights, discuss challenges, and compare perspectives on how liquid biopsy is shaping the future of oncology.

This interactive format promises to create a rich learning environment, making this a must-attend event for those interested in the cutting-edge applications of liquid biopsy.

## 17:30 – 19:00 Young Career Round Tables

Spruce 3-4

### 17:30 – 17:40 Chairs

Konstantinos Venetis, IEO, European Institute of Oncology - Italy  
Eleonora Nicolò, Weill Cornell Medicine - United States  
Carolina Reduzzi, Weill Cornell Medicine - United States

### 17:40 – 19:00 Roundtable Panel

Simon Heeke, UT MD Anderson Cancer Center - United States  
Julia Burnier, McGill University - Canada  
Luca Quagliata, Thermo Fisher Scientific - Italy  
Bruna Pellini, Moffitt Cancer Center - United States

## MONDAY, NOVEMBER 25, 2024

### 08:00 – 09:00 Industry Symposium: OneCell Diagnostics

Adams B



#### Chartering the Future of Liquid Biopsy: ctDNA + CTC Multi-omics (DNA+RNA+Proteins)

Leading liquid biopsy experts Dr David Gandara and Dr Christian Rolfo and other panelists will discuss the landscape of blood-based biomarkers for therapy response and resistance. They will focus on platforms for blood-based RNA and Proteomics, including CTCs, highlighting the latest scientific evidence from ASCO and AACR supporting the utility of these platforms.

Why is this important?

ctDNA based liquid biopsy panels have been adequate for targeted therapy and immunotherapy response and resistance monitoring. However, with the approval of new therapies, including ADC (antibody drug conjugates) and Bi-specifics, it has become important to integrate highly sensitive, multiplexed blood-based RNA/transcriptomics and Proteomics to detect markers of response and resistance.

### 09:00 – 10:30 OA01. Preferred Abstracts

Adams B

#### 09:00 – 09:05 Chairs

Carolina Reduzzi, Weill Cornell Medicine - United States  
Diego De Miguel Perez, The Ohio State University - United States

#### 09:05 – 09:10 OA01.01 Predicting Genitourinary Cancer Tissue-of-origin Using Urine Cell-free DNA Fragmentomic Features

Pradeep Chauhan, Mayo Clinic - United States

#### 09:10 – 09:25 OA01.02 Circulating T-cell Receptor Repertoire Analysis Improves Cancer Early Detection

Roman Yelensky, Serum Detect, Inc. - United States

**09:25 – 09:30** **OA01.03 Cerebrospinal Fluid Circulating Tumour DNA Profiling for Risk Stratification and Matched Treatment for Central Nervous System Metastases of NSCLC**

Meimei Zheng, Guangdong Provincial People's Hospital - China

**09:30 – 09:45** **OA01.04 Discovering New Markers to Optimize the Detection of Circulating Tumor Cells**

Sina Naserian, ScreenCell - France

**09:45 – 09:50** **OA01.05 Real-World Experience of the Decentralized MSK-ACCESS powered with SOPHiA DDM Solution**

Florian Klemm, SOPHiA Genetics - Switzerland

**09:50 – 09:55** **OA01.06 Expanding clinical impact of liquid biopsy beyond genomics: exploration of novel epigenomic applications**

Leslie Bucheit, Guardant Health - United States

**10:30 – 11:30** **Morning Break Exhibits/Posters**

Exhibit Hall (Adams C-D)



**REFRESHMENTS PROVIDED**

**11:30 – 13:00** **S09. Accreditations and Minimal Requirements for Liquid Biopsy**

Adams B

**11:30 – 11:35** **Chairs**

Umberto Malapelle, ISLB - Italy

Nicola Fusco, European Institute of Oncology - Italy

**11:35 – 11:50** **S09.01 Liquid Biopsy Laboratory Accreditation Process**

Silvia Calabuig Fariñas, University of Valencia - Spain

**11:50 – 12:05** **S09.02 The Policy for Accreditation Process**

Denis Horgan, European Alliance For Personalised Medicine - Belgium

**12:05 – 12:20** **S09.03 Minimal Requirements for ctDNA Testing on Liquid Biopsy in Solid Tumors: ISLB Quality Control & Accreditations Committee Working Group**

Konstantinos Venetis, IEO, European Institute of Oncology - Italy

**12:20 – 12:35** **S09.04 Minimal Requirements in Bioinformatic for Accreditation**

Giovanni Nigita, The Ohio State University Comprehensive Cancer Center - United States

**12:35 – 13:00** **Panel Discussion**

Aadel Chaudhuri, Mayo Clinic - United States

Maria Jose Serrano, ISLB - Spain

**13:30 – 14:00** **Best Abstract Award & Closing Ceremony**

Adams B

# ISLB Awards Lectures



**Dr. Luis Diaz**

## S04.01 Application of Circulating Tumor DNA Analyses to Unmet Clinical Needs

### ISLB Lifetime Achievement Award

Dr. Diaz is a pioneer in cancer genomics. His teams were the first to track circulating tumor DNA for the early detection of cancer, tracking resistance and for the detection of minimal residual disease; and discover the therapeutic link between cancer genetics and immunotherapy in mismatch repair deficient tumors.



**Prof. Ellen Heitzer**

## S04.02 ctDNA – From Proof-of-Principle to Clinical Implementation

### ISLB Research Award

Ellen Heitzer is a Clinical Laboratory Geneticist at the Institute of Human Genetics in Graz, AUSTRIA. She is heading the Research Unit for “Liquid Biopsies for personalized medicine in cancer”.



**Prof. Dennis Lo**

## S04.03 Frontiers in Cell-free DNA Fragmentomics

### ISLB Innovation in Liquid Biopsy Award

Professor Lo discovered the presence of cell-free fetal DNA in maternal blood in 1997. He has spearheaded the development of non-invasive prenatal testing (NIPT) which is now used worldwide. He has also pioneered technologies for the detection of cancer using peripheral blood.



# Welcome Reception

We invite all delegates to join us for the Welcome Reception marking the beginning of an exciting few days filled with dynamic presentations, insightful posters, and a comprehensive exhibition. This event offers an opportunity for attendees to connect and network with peers and colleagues.

Supported by

**ThermoFisher**  
SCIENTIFIC

Date: Saturday, November 23, 2024

Time: 18:15 - 20:30

Location: Exhibit Hall, Adams C-D

Congress Badge is required for entry\*\*

# Congress Partners

ISLB 2024 would like to thank our generous Partners & Supporters.

## GOLD



## SILVER



## BRONZE



## SUPPORTERS



# Exhibit & Poster Hall Information

## Exhibit Hall and Poster Hours

Saturday, November 23 10:30 - 16:00  
18:15 - 20:30  
Sunday, November 24 10:00 - 15:00  
Monday, November 25 10:00 - 12:00

## Welcome Reception Supported by

**ThermoFisher**  
SCIENTIFIC

Saturday, November 23 18:15 - 20:30

## Showcase Theatre

Sunday, November 24 10:40 - 11:00

 **ONCOHOST**  
GUIDED ONCOLOGY


Sunday, November 24 11:10 - 11:30

  
**QIAGEN**

# Exhibit Hall Floorplan

## Exhibitors

ANGLE	111
Biofidelity	310
Bio-Rad Laboratories	210
Caris Life Sciences	105
DNA Genotek	304
Foundation Medicine	302
GT Molecular	211
J&J Innovative Medicine	103
Menarini Silicon Biosystems	309
OncoHost	203
OneCell Diagnostics	303
Pfizer Oncology	109
QIAGEN	209
Tecan	311
Tempus	204
Tethis S.p.A.	305
Thermo Fisher Scientific	205



# Exhibitor Listing



## ANGLE | Booth #111

ANGLE is a world-leading liquid biopsy company based in the UK, its patented Parsortix® PC1 system is the first FDA cleared device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood.

[angleplc.com](http://angleplc.com)



## Biofidelity | Booth #310

Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to improving and extending the lives of patients with cancer by enabling better targeting of therapies, early detection of treatment resistance and routine monitoring of treatment response. Visit [biofidelity.com](http://biofidelity.com) and connect with us on LinkedIn and X.

[biofidelity.com](http://biofidelity.com)



## Bio-Rad Laboratories | Booth #210

Bio-Rad is a global leader of innovative products for life sciences and clinical diagnostics. Our technologies focus on bioprocessing, protein characterization, and cell and 'omics analyses to advance scientific discovery and improve healthcare. Our customers include universities, research facilities, hospitals, public health and commercial labs, biopharma, and applied laboratories.

[bio-rad.com](http://bio-rad.com)



## Caris Life Sciences | Booth #105

Caris Life Sciences® is the leading molecular science and technology company developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins, revealing a molecular blueprint helping physicians better detect, diagnose and treat patients.

[carislifesciences.com](http://carislifesciences.com)



## DNA Genotek | Booth #304

DNA Genotek Inc. distributes Colli-Pee™ devices for self-collected, volumetric first-void urine sampling, enhancing the quality of diagnostic tests for infectious diseases and oncology. Backed by strong clinical research outcomes and patient preference, the Colli-pee device standardizes collection, and enables the immediate mixing of urine with preservative for sample stability.

[dnagenotek.com](http://dnagenotek.com)

---



## Foundation Medicine | Booth #302

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. We are driven to help our partners find answers and take action as we work to transform cancer care.

[foundationmedicine.com](http://foundationmedicine.com)

---



## GT Molecular | Booth #211

GT Molecular provides ultrasensitive digital and Real-Time PCR assays for pathogen quantification and advancing cancer research. Our multiplex oncology (RUO) assay kits are optimized and validated using real patient samples, providing high-performance, easy-to-use results with primers, probes, and controls included. Sample logistics management, PCR and NGS testing services also available.

[gtmolecular.com](http://gtmolecular.com)

---

---

## Johnson & Johnson

### J&J Innovative Medicine I Booth #103

Patients inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, we confidently address some of the most complex diseases of our time and unlock the potential medicines of tomorrow. Our diverse portfolio spans multiple therapeutic areas — Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way.

[janssen.com](http://janssen.com)



### Menarini Silicon Biosystems I Booth #309

Menarini Silicon Biosystems' CLIA lab uses CELLSEARCH® to offer a minimally invasive approach to follow a cancer patient's therapeutic journey by providing a standardized and reliable count of circulating tumor cells. MenariniSearch comprehensive genomic profiles identify a broader range of genetic alterations, empowering you to discover novel biomarkers and therapeutic targets.

[siliconbiosystems.com](http://siliconbiosystems.com)



### OncoHost I Booth #203

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. Its PROphet® platform is a plasma-based proteomic pattern analysis tool whose NSCLC test guides first-line immunotherapy decisions. OncoHost is led by an experienced team of entrepreneurs and industry experts, supported by a large-scale clinical trial.

[oncohost.com](http://oncohost.com)



## OneCell Diagnostics | Booth #303

OneCell Diagnostics Inc. is a Cupertino, USA-based precision oncology company specializing in liquid biopsy, single-cell multiomics, and digital pathology innovations. Incorporated in India, the company operates its Research and Diagnostic labs in California, USA, and Pune, India. OneCell Diagnostics is on a mission to democratize precision cancer monitoring and surveillance for early detection of cancer recurrence. By leveraging genomics data and Artificial Intelligence (AI), OneCell Diagnostics aims to impact millions of cancer patients worldwide, offering high-quality precision therapy options to those in need.

[onecelldx.com](http://onecelldx.com)



## Pfizer Oncology | Booth #109

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

[pfizer.com](http://pfizer.com)



## QIAGEN | Booth #209

QIAGEN serves more than 500,000 customers globally, all seeking insights from DNA, RNA and proteins. Using any biological sample, they are advancing science and improving outcomes for people everywhere. Our products for molecular testing serve applications from basic life sciences research to clinical healthcare. Together, we are making improvements in life possible.

[qiagen.com](http://qiagen.com)



## Tecan | Booth #311

Tecan's purpose is to improve people's lives and health by empowering customers to scale healthcare innovation globally, from life science to the clinic. We collaborate with our customers in healthcare and the life sciences, from early-stage innovation through project implementation and beyond. We deliver the products, services and solutions that make lab processes and medical procedures precise, reproducible and compliant. Together, we are shaping a brighter, healthier future, for patients across the world.

[tecan.com](http://tecan.com)



## Tempus | Booth #204

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

[tempus.com](http://tempus.com)



## Tethis S.p.A. | Booth #305

Tethis S.p.A., an Italian diagnostic company, is introducing the first automated platform that standardizes plasma and cytology sample preparations for multiomics liquid biopsy.

[tethis-lab.com](http://tethis-lab.com)



## Thermo Fisher Scientific | Booth #205

Thermo Fisher Scientific Inc. is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We are committed to enabling advancements in precision oncology through our Ion Torrent brand of next-generation sequencing (NGS) instrumentation and Oncomine portfolio of assays, democratizing access to molecular profiling through fast, automated, and reliable solutions.

[oncomine.com](http://oncomine.com)



# PUSH THE BOUNDS OF SCIENCE

## MAKE LIFE-CHANGING MEDICINES

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories.

Learn more at [www.regeneron.com/global](http://www.regeneron.com/global)

**REGENERON**<sup>®</sup>

Copyright © 2024 Regeneron Pharmaceuticals, Inc. All rights reserved. US-UNB-EM-24-07-0002 September 2024

# General Congress Information



## Venue

**Gaylord Rockies Convention Center**  
6700 N Gaylord Rockies Blvd., Aurora,  
CO 80019



## Access / Security

Name badges will be provided to all attendees, sponsors, and exhibitors and will be available for pick up at the Registration Desk (see venue map). Please wear your badge at all times as it is your admission to all Congress sessions, Exhibit & Poster Hall, and non-ticketed social events. Any lost badges will incur a 50 EUR reprint fee.



## Language

The official language of ISLB 2024 is English. All sessions will be conducted in English.



## Parking

Self-Parking: \$33 plus tax  
Valet: \$48 plus tax per night.

Tell your check-in agent you have a vehicle on the property for unlimited access in and out of the resort gates (self-park \$33.00, valet \$48.00 plus tax per night). You are welcome to unload your vehicle on the front drive; however, cars are not permitted to be left unattended.



## Lost Property

Please report any lost or unattended items immediately to the ISLB 2024 Registration Desk. Should you lose anything while at Congress, please enquire at the Registration Desk where any recovered lost property will be held. At the end of the congress, all unclaimed lost and found items will be given to Gaylord Rockies Convention Center.



## Morning Breaks

Refreshments provided

Location: Exhibit Hall (Adams C-D)

November 23: 11:00 – 12:30

November 24: 10:30 – 12:00

November 25: 10:30 – 11:30



## Registration Hours

Location: Adams B Foyer

November 22: 15:00 – 20:00

November 23: 07:00 – 20:00

November 24: 07:00 – 19:00

November 25: 07:00 – 12:00



## Wi-Fi

Wi-Fi is complimentary if staying at the resort.



6<sup>TH</sup> ANNUAL CONGRESS  
**Liquid Biopsy**  
November 23-25, 2024 | Denver, Colorado, USA

# Mobile App



Google Play



App Store



Alternatively, please search for the “The Event App by EventsAIR” in your respective App Store.

Once downloaded, enter the following

Event Code

Login using the email address and PIN sent to you in your final confirmation email. Please do not share the PIN number; it is your unique PIN connected to your registration record.

*See You at*  
**ISLB 2025**  
in Orlando, USA!

November 1-3,  
2025

GET SOCIAL!



**#ISLB25**



**2025.islb.info**



# Poster Listing

---

## Advocacy & Regulatory Aspects of Liquid Biopsy

PP01.01

**Developing Novel Primary Reference Materials to Support Standardisation in Liquid Biopsy.**

Leandro Lo Cascio, United Kingdom

PP01.02

**External Quality Assurance for Circulating Free (cfDNA) Testing in Prostate Cancer: Observations and Future Perspectives.**

Arfa Maqsood, United Kingdom

---

## Clinical Applications of Liquid Biopsy

PP01.04

**Methylation Based ctDNA Serial Monitoring Correlates with Immunotherapy Response in Non-Small Cell Lung Cancer**

Angela Hsiao, United States

PP01.06

**Novel Technology Affords Real-Time PCR the Sensitivity Required for Minimal Residual Disease Monitoring**

Mary Stischer, United States

PP01.05

**Characterization of Plasma Cell Free DNA Variants as Tumor-derived vs. Clonal Hematopoiesis of Indeterminate Potential (CHIP) in 11,457 Cancer Patients**

Daniel Magee, United States

PP01.07

**Real World Circulating Tumor DNA Detection in Advanced Pan-cancers by Timing of Liquid Biopsy Relative to Therapy**

Vivek Subbiah, United States

---

## Clinical Applications of Liquid Biopsy

PP01.08

### **Liquid Biopsy for Monitoring Response in KRAS-Mutated NSCLC Patients Treated with First-Line Immunotherapy**

Ester Munera-Maravilla, Spain

PP01.09

### **Association of Circulating Tumor DNA Genotyping and Computed Tomography Radiomics with Clinical Outcomes in Patients with Advanced NSCLC**

Alberto Ranghiero, Italy

PP01.10

### **NSCLC Exosomes: Unlocking Biomarker Potential**

Susana Torres-Martínez, Spain

---

## Clinical Applications of Liquid Biopsy

PP01.11

### **Detection of ctDNA After Neoadjuvant Chemotherapy Predicts Distant Relapse-Free Survival, Local and Distant Recurrence in TNBC: Findings from TRICIA Study**

Talia Roseshter, Canada

PP01.12

### **High-sensitivity Detection and Broad Genomic Profiling in HR+/HER2- Breast Cancer: Final Comparative Results Using Targeted Single-gene and Broad-panel Sequencing Assays**

Marija Balic, United States

PP01.13

### **Optimization and Evaluation of a Novel CTC Culture Protocol Using 'Reset' Vascular Endothelial Cells (R-VECs) and Microfluidic Enrichment.**

Nadia Bayou, United States

PP01.14

### **Clinical Utility of Body Fluids for Multiplexed Detection of Genetic Alterations in Cancer Patients.**

Beatriz Beatriz Garcíam, España

PP01.15

### **Determination of Tumor PSMA Expression and Lutetium-PSMA Response in Men With Prostate Cancer Using a Novel Epigenomic Liquid Biopsy Platform**

Praful Ravi, United States

PP01.16

### **Circulating Tumor DNA as Part of the Routine Work-up for Patients with Suspected Advanced Lung Cancer**

Tia Brasoveanu, Canada

PP01.17

**A First-Line Approach: Liquid Biopsy-Guided Osimertinib Therapy for EGFR-Mutated NSCLC**

Silvia Calabuig-Fariñas, Spain

PP01.18

**Next Gen Liquid Biopsy: Comprehensive Analysis from a Single Tube of Blood**

Jon Ladd, United States

PP01.19

**Expert Opinion Recommendations for External Quality Assessment for Liquid Biopsy Testing from the European Liquid Biopsy Society ctDNA Workshop**

Zandra Deans, United Kingdom

PP01.21

**Transforming the Lung Cancer Diagnostic Pathway with Liquid Biopsy: Early Genomic Results from the QuicDNA Biomarker Study in Wales**

Rachel Dodds, United Kingdom

PP01.22

**Characterizing cell-free DNA from healthy BRCA2-999del5 carriers**

Berglind Ósk Einarsdóttir, Iceland

PP01.23

**ASPYPE-Lung Blood: Validation Of A Simple, Fast and Robust Method For Molecular Profiling Of Actionable Variants In Plasma**

Ryan Evans, United States

PP01.24

**Monitoring GALNT13 in Blood of NSCLC Patients With Serial Evaluation Using Digital RT-PCR. A potential New Liquid Biopsy Biomarker**

Eugenia Fernández Armúa, Uruguay

PP01.25

**Impact on the Therapeutic Decision of Massive Gene Sequencing (NGS) in Plasma From Patients With Advanced Cancer.**

Leonor Fernández-Murga, España

PP01.26

**An mDETECT Assay for Monitoring Treatment Response in Metastatic Breast Cancer Patients**

Keira Frosst, Canada

PP01.27

**Liquid biopsy in Real-life: Experience of a Cancer Center Collecting Samples From Multiple Institutions in an Italian Regional Cancer Network**

Gianluca Sacco, Italia

PP01.28

**Expanding the Impact of Liquid Biopsies in Patients with Newly Diagnosed Advanced Lung Cancer (ExpandingLUNG)**

Adrian G. Sacher, Canada

PP01.29

**BRAF V600 Mutations Detection in Melanoma: A Cross-Methodological Study Using cfDNA**

Eloisa Jantus Lewintre, España

PP01.30

**Expression of Programmed Death - Ligand 1 as a Dynamic Biomarker on Circulating Tumor Cells in Pancreatic Cancer Patients**

Jayant Khandare, India

PP01.31

**Transit of Circulating Tumor Cells (Ctc) Post Radiotherapy at Irradiated Tumor Regions in Pan-Cancer Patients**

Jayant Khandare, India

PP01.32

**Comprehensive Analysis of ctDNA and CTCs Reveals Resistance Signatures and Correlations with PET Scan Outcomes in Cancer Patients**

Gowhar Shafi, India

PP01.33

**Downstream Effector Mutations Indicate Potential Tyrosine Kinase Inhibitor Resistance in EGFR Mutated Lung Cancer Patients**

Gowhar Shafi, India

PP01.34

**Evaluation of a New Vacuum Blood Collection Tube for Cell-Free DNA**

□ Kuniya Komai, Japan

PP01.35

**DISCOVER: Plasma Testing in Patients With Advanced Undergenotyped NSCLC and in Targeted Therapy Resistance.**

Abdulrahman Alghabban, Canada

PP01.37

**Multimodal Urine-based Accurate and Non-invasive Tool for Predicting Immunotherapy Response in Bladder Cancer**

Álvaro Martín de Bernardo, Spain

PP01.38

**Genomic-epigenomic ctDNA Testing in Metastatic Breast Cancer Patients with no Evidence of Disease: Potential Clinical Utility from Real-world Data**

Caterina Gianni, United States

PP01.39

**Development of an Expert Consensus on the Clinical Utility of Circulating Tumor Cells in Solid Tumors**

Eleonora Nicolò, United States

PP01.40

**Circulating Tumor DNA Mutations as Markers for Brain Metastases at Diagnosis and During Treatment**

Rodrigo Paredes de la Fuente, United States

PP01.41

**Multimomics Analysis in Longitudinal Series of Plasma Samples of p.G12NSCLC Patients Under Target Treatment**

Francesco Pepe, Italy

PP01.42

**MicroOrganoSphere (MOS): A Novel Technology for Circulating Tumor Cell (CTC)- derived Organoid Formation**

Elisabetta Molteni, United States

PP01.43

**Liquid Biopsy Detection of Gene Copy Number (CN) Losses Including Existing and Emerging Clinical Targets**

Christian Rolfo, United States

PP01.44

**Comprehensive Circulating Cytokine/Chemokine Profiles for Monitoring and Predicting Clinical Outcomes in Melanoma Neoadjuvant Immunotherapy**

Dhruvajyoti Roy, United States

PP01.45

**Circulating Tumor DNA (ctDNA) Analysis for Precision Oncology: A Tertiary Oncology Centre Perspective in India**

Omshree Shetty, India

PP01.46

**Pan-Cancer Analysis of Pre-Treatment Circulating Tumor DNA (ctDNA) in Patients from the Princess Margaret Liquid Biopsy Program**

Scott Strum, Canada

PP01.47

**Ultra-sensitive Molecular Residual Disease Detection Through Whole Genome Sequencing with Single-read Error Correction**

John Kern, United States

PP01.48

**Evaluation of Full Spectrum Cell-free RNA in Peripheral Blood as Potential Biomarker for Acute myeloid leukemia disease profiling**

Deepshi Thakral, India

PP01.51

**ESR1 ctDNA Testing in HR+/HER2 Metastatic Breast Cancer: A Real-world Perspective From a Referral Laboratory**

Konstantinos Venetis, Italy

PP01.52

**ctDNA-Based Detection of Homologous Recombination Deficiency in mCRPC Patients**

Georgios Vlachos, Austria

---

## Clinical Trials Including Liquid Biopsies

PP01.53

**Pioneering South Florida's First Minority-Focused Breast Cancer Biorepository: Leveraging Liquid Biopsy, NGS, and ctDNA for Advancements in Precision Medicine**

Andres Alvarez Pinzon, United States

PP01.54

**Exploratory Analysis of ctDNA and Imaging Response in Phase I/II CHORUS Study of Canakinumab With Chemoradiation and Durvalumab for NSCLC**

Karmelina Charalambous, United States

PP01.55

**The SURVIVE Study - Liquid Biopsy Guided Surveillance in Intermediate- to high-risk Early Breast Cancer**

Christodoulos Pipinikas, United States

PP01.56

**A Randomized Trial of Immune Checkpoint Inhibitor Plasma Proteomic Biomarker and Chemotherapy Risk Model in Advanced Non-Small Cell Lung Cancer**

Surbhi Singhal, United States

---

## Composite Biomarkers Using Liquid Biopsy

PP01.58

**Fluorescent dCFPyL (GUL-Cy5) for Detecting Circulating Tumor and Immune Cells Containing Cancer Extracellular Vesicles in Early Metastatic Prostate Cancer Prognostication**

Omar Alawamry, Canada

PP01.59

**Identification of Genomic Features Associated with ctDNA Shedding in Non Small Cell Lung Cancer**

Anna Di Lello, United States

PP01.60

**GFAP, UCH-L1, Tau and NfL as Potential Biomarkers for Glioblastoma Diagnosis and Monitoring: a Retrospective Study**

Jonathan Decarpentrie, Belgium

PP01.61

**Liquid Biopsy-Derived Proteomic Signature for Tailoring Non-Small Cell Lung Cancer Immunotherapy Strategies**

Michal Harel, Israel

PP01.62

**Non-invasive Immunogram to Characterize and Monitor Immune Status in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.**

Andrea Moreno-Manuel, España

PP01.63

**Algorithmic Genomic Alteration Filtering and Circulating Tumor DNA (ctDNA) Quantification in Serial Liquid Biopsy (LBx) From Patients With ProstateCancer**

Umberto Malapelle, Italy

PP01.64

**Computational Variant Origin Prediction (VOP) to Distinguish Germline, Tumor Somatic, and Clonal Hematopoiesis (CH) Variants in Liquid Biopsy (LBx)**

Bruna Pellini, United States

---

## Comprehensive Liquid Biopsy Analysis in Different Matrices

PP01.67

**Assessing Mutational Status in NSCLC through Exosomal Liquid Biopsies**

Susana Torres-Martínez, Spain

PP01.68

**DEGs Analysis of Circulating Tumor Cells (CTCs) and Tissue Tumor Cells in Costa Rican HER2 Positive Metastatic Breast Cancer Patients.**

Ricardo Chinchilla-Monge, Costa Rica

---

## Liquid Biopsy in Early Cancer Detection

PP01.73

**Circulating Tumour Cell Isolation and Enrichment for Investigation of Prostate Cancer Metastasis**

Sophia Abusamra, United States

PP01.74

**Analytical Results of a Tumor-informed Digital Droplet PCR Approach for Minimal Residual Disease**

Anna Klemantovich, Canada

PP01.75

**Identification of Tumor-marker Gangliosides in Serum for Early-Stage Cancer Diagnosis**

Rachel Culp-Hill, United States

PP01.76

**Characterizing the Cell-free Transcriptome in a Humanized DLBCL Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting**

Philippe Decruyenaere, Belgium

PP01.77

**Minimally Invasive Image Guided Percutaneous Lung Nodule Resection for Definitive Diagnosis and Treatment of Lung Cancer**

Richard Fischel, CA

PP01.78

**Advanced CNA-Informed Fragmentomics Enhances Cross-Cohort Tumor Detection**

Piera Grisolia, United States

PP01.79

**Enhancing Sensitivity of ctDNA Copy Number Detection by Increasing Plasma Sample Volume**

Nafiseh Jafari, United States

PP01.80

**Potential of Circulating MicroRNAs as Biomarkers in Perioperative Management of Lung Cancer**

Joji Samejima, Japan

PP01.81

**Smart BioSurface® Technology for Prostate Cancer Detection and Risk Stratification through CTC Enumeration and Biomarker Expression Profiling**

Francesca Senic-Matuglia, Italy

PP01.82

**Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients with Unbiopsied Lung Tumors (SABR-DETECT)**

Saurav Verma, Canada

---

## Liquid Biopsy in Non-Oncological Conditions

PP01.83

**Cell-Free RNA Liquid Biopsies Uncover Transcriptional Networks Underlying Sepsis**

Nicholas Semenkovich, United States

PP01.84

**Optimizing High-Quality RNA Retrieval from Dried Blood Microsamples for RNA Sequencing**

Elena Ramos Varas, Belgium

## Miscellaneous

PP01.86

### Automated Analysis Pipeline for HER2 Expression Profiling in CTCs: Computational Potential for Advancing Personalized Therapy for Metastatic Breast Cancer

Sarah Henretta, United States

PP01.87

### Trends in Physician Perception and Use of Liquid Biopsy in NSCLC within the US

Hope Bender, United States

PP01.88

### Assessing the Performance of cfDNA Extraction from Plasma

Zandra Deans, United Kingdom

PP01.89

### Economic and Clinical Impact of Integrating the PROphetNSCLC Plasma Proteomic Test in mNSCLC Treatment

Yehonatan Elon, Israel

PP01.90

### Unlocking the Full Potential of Liquid Biopsy: A Polymer Method for the Reagent-free Recovery and Storage of DNA from Biofluids

Matthew Owens, United Kingdom

*NOW ENROLLING*

**SOHO-02** A Phase 3 open-label, randomized, multicenter trial to evaluate efficacy and safety of oral BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic **NSCLC with HER2-activating mutations**

For complete information please visit:  
<http://www.clinicaltrials.gov> (NCT06452277)



 **SOHO 02**  
CLINICAL STUDY

© 2024 Bayer.  
Bayer and the Bayer Cross are registered trademarks of Bayer.  
MA-PFM-ONC-US-0431-1 09/2024